Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
D. Ross Camidge,Marcello Tiseo,Myung-Ju Ahn,Karen L. Reckamp,Karin Holmskov Hansen,Sang-We Kim,Rudolf M. Huber,Howard West,Harry Grön,Maximilian Hochmair,Natasha B. Leighl,Scott N. Gettinger,Corey J. Langer,Luis Paz-Ares,Egbert F. Smit,Edward Y. Kim,William Reichmann,Tim Clackson,David Kerstein,Frank G. Haluska,Dong-Wan Kim JOURNAL OF THORACIC ONCOLOGY（2017）
关键词
ALK,brigatinib,NSCLC,TKI
AI 理解论文
溯源树
样例
